Please login to the form below

Not currently logged in


This page shows the latest NKTR-102 news and features for those working in and with pharma, biotech and healthcare.

Nektar hit by breast cancer trial setback

Nektar hit by breast cancer trial setback

Nektar hit by breast cancer trial setback. NKTR-102 failed to meet phase III targets. ... The development is also particularly disappointing for Nektar as NKTR-102 was a wholly owned project.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....